Efavirenz

Generic Name: Efavirenz

Brand Names: Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₉ClF_₃NO_₂

CAS Number: 154598-52-4

Unique Ingredient Identifier: JE6H2O27P8

Background: Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
...

Indication: For use in combination treatment of HIV infection (AIDS)

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022

Phase 2

Terminated

Conditions: HIV-1

Interventions: Drug: lersivirine
Drug: etravirine
Drug: efavirenz

First Posted Date: 2010-12-06

Last Posted Date: 2014-06-09

Lead Sponsor: Pfizer

Target Recruit Count: 108

Registration Number: NCT01254656

Locations: 🇬🇧
Pfizer Investigational Site, London, United Kingdom

TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir

Phase 1

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: TMC435
Drug: TMC435 + raltegravir
Drug: TMC435 + efavirenz
Drug: efavirenz
Drug: raltegravir

First Posted Date: 2010-11-16

Last Posted Date: 2012-11-08

Lead Sponsor: Tibotec Pharmaceuticals, Ireland

Target Recruit Count: 48

Registration Number: NCT01241773

Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression

Phase 4

Terminated

Conditions: Mitochondrial Dysfunction
HIV Infection

Interventions: Drug: Atazanavir/ritonavir
Drug: Efavirenz

First Posted Date: 2010-09-03

Last Posted Date: 2017-08-11

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 1

Registration Number: NCT01194856

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells

Phase 4

Withdrawn

Conditions: HIV Infections
Acquired Immune Deficiency Syndrome

Interventions: Drug: Raltegravir plus Truvada
Drug: Atripla

First Posted Date: 2010-08-02

Last Posted Date: 2017-06-14

Lead Sponsor: Community Research Initiative of New England

Registration Number: NCT01173510

Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection

Phase 4

Completed

Conditions: HIV Infection
Hepatitis C, Chronic

Interventions: Drug: Efavirenz
Drug: Raltegravir

First Posted Date: 2010-06-22

Last Posted Date: 2021-08-13

Lead Sponsor: University of Hawaii

Target Recruit Count: 80

Registration Number: NCT01147107

Locations: 🇻🇳
Viet Tiep General Hospital, Hai Phong, Vietnam
🇻🇳
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers

Not Applicable

Completed

Conditions: Efavirenz, Metabolism and Pharmacokinetics Changes

Interventions: Drug: Efavirenz
Drug: voriconazole

First Posted Date: 2010-04-15

Last Posted Date: 2014-12-17

Lead Sponsor: Indiana University

Target Recruit Count: 61

Registration Number: NCT01104376

Locations: 🇺🇸
Indiana University, Indianapolis, Indiana, United States

GSK1349572 Drug Interaction Study With Efavirenz

Phase 1

Completed

Conditions: Infections, Human Immunodeficiency Virus and Herpesviridae

Interventions: Drug: GSK1349572
Drug: Efavirenz

First Posted Date: 2010-04-02

Last Posted Date: 2017-09-25

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 12

Registration Number: NCT01098526

Locations: 🇺🇸
GSK Investigational Site, Buffalo, New York, United States

Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Phase 3

Completed

Conditions: HIV Infections
HIV

Interventions: Drug: Stribild
Drug: Atripla
Drug: Stribild Placebo
Drug: Atripla Placebo

First Posted Date: 2010-03-30

Last Posted Date: 2015-11-11

Lead Sponsor: Gilead Sciences

Target Recruit Count: 707

Registration Number: NCT01095796

Locations: 🇺🇸
Kaiser Permanente, Los Angeles, California, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Anthony Mills, MD, Inc., Los Angeles, California, United States

and more 99 locations

Sustiva Levels With Use of a Gel Capsule

Phase 4

Completed

Conditions: HIV
HIV Infections

Interventions: Drug: Over-encapsulated efavirenz
Drug: Efavirenz

First Posted Date: 2010-03-16

Last Posted Date: 2017-03-09

Lead Sponsor: University of Minnesota

Target Recruit Count: 16

Registration Number: NCT01087814

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

Cryptococcal Optimal ART Timing Trial

Phase 4

Completed

Conditions: AIDS
Cryptococcal Meningitis
HIV Infections

Interventions: Drug: efavirenz
Biological: nucleoside

First Posted Date: 2010-02-24

Last Posted Date: 2020-06-09

Lead Sponsor: University of Minnesota

Target Recruit Count: 177

Registration Number: NCT01075152

Locations: 🇺🇬
Mbarara University of Science and Technology, Mbarara, Uganda
🇺🇬
Infectious Disease Institute, Mulago Hospital, Makerere University, Kampala, Uganda
🇿🇦
GF Jooste Hospital, Cape Town, South Africa

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy